{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:47:31Z","timestamp":1792075651189,"version":"4.4.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170872"],"award-info":[{"award-number":["82170872"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92057116"],"award-info":[{"award-number":["92057116"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["XDA12040328"],"award-info":[{"award-number":["XDA12040328"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["20S11903400"],"award-info":[{"award-number":["20S11903400"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["21ZR1475300"],"award-info":[{"award-number":["21ZR1475300"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.apsb.2022.06.011","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T22:24:23Z","timestamp":1655504663000},"page":"739-753","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia"],"prefix":"10.1016","volume":"13","author":[{"given":"Zhifu","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaolei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0420-584X","authenticated-orcid":false,"given":"Min","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chendong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianpeng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3457-8153","authenticated-orcid":false,"given":"Jingya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fajun","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2022.06.011_bib1","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the european atherosclerosis society consensus panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.apsb.2022.06.011_bib2","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.apsb.2022.06.011_bib3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the american college of cardiology\/american heart association task force on practice guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.apsb.2022.06.011_bib4","first-page":"S139","article-title":"Epidemiology and management of hyperlipidemia","volume":"23","author":"Karr","year":"2017","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.apsb.2022.06.011_bib5","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2337\/db16-0046","article-title":"Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol","volume":"65","author":"Xiao","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2022.06.011_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrcardio.2011.2","article-title":"Pharmacological strategies for lowering LDL cholesterol: statins and beyond","volume":"8","author":"Brautbar","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.apsb.2022.06.011_bib7","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1001\/jama.2016.15450","article-title":"Statin use for the primary prevention of cardiovascular disease in adults: us preventive services task force recommendation statement","volume":"316","author":"Uspst","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.apsb.2022.06.011_bib8","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.115.019014","article-title":"Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of west of scotland coronary prevention study","volume":"133","author":"Ford","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.apsb.2022.06.011_bib9","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1059344","article-title":"Structural mechanism for statin inhibition of HMG-CoA reductase","volume":"292","author":"Istvan","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.apsb.2022.06.011_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cmet.2015.08.002","article-title":"Statin-induced myopathy is associated with mitochondrial complex iii inhibition","volume":"22","author":"Schirris","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.apsb.2022.06.011_bib11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism","volume":"8","author":"Golomb","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.apsb.2022.06.011_bib12","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2022.06.011_bib13","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/JCN.0b013e3181b4bab4","article-title":"Evidence-based guidelines for cardiovascular risk reduction: the safety and efficacy of high-dose statin therapy","volume":"24","author":"Ashen","year":"2009","journal-title":"J Cardiovasc Nurs"},{"key":"10.1016\/j.apsb.2022.06.011_bib14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MOL.0000000000000114","article-title":"Pcsk9 and ldlr degradation: regulatory mechanisms in circulation and in cells","volume":"25","author":"Lagace","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.apsb.2022.06.011_bib15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of african descent resulting from frequent nonsense mutations in pcsk9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2022.06.011_bib16","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2022.06.011_bib17","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated ldl cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2022.06.011_bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.apsb.2022.06.011_bib19","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s40265-016-0613-0","article-title":"Unmet needs in LDL-C lowering: when statins won't do","volume":"76","author":"Krahenbuhl","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2022.06.011_bib20","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrcardio.2013.117","article-title":"Pharmacotherapies for lipid modification: beyond the statins","volume":"10","author":"Gotto","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.apsb.2022.06.011_bib21","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/brv.12178","article-title":"De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose","volume":"91","author":"Sanders","year":"2016","journal-title":"Biol Rev Camb Philos Soc"},{"key":"10.1016\/j.apsb.2022.06.011_bib22","first-page":"277","article-title":"Dietary carbohydrates and fatty liver disease: de novo lipogenesis","volume":"21","author":"Chiu","year":"2018","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.apsb.2022.06.011_bib23","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1146\/annurev.nu.16.070196.002515","article-title":"Regulation of hepatic de novo lipogenesis in humans","volume":"16","author":"Hellerstein","year":"1996","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.apsb.2022.06.011_bib24","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1016\/S0021-9258(18)69735-2","article-title":"The citrate cleavage enzyme. I. Distribution and purification","volume":"234","author":"Srere","year":"1959","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.06.011_bib25","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1038\/s41418-020-0491-6","article-title":"Inhibition of the mitochondrial citrate carrier, SLC25A1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD\/NASH","volume":"27","author":"Tan","year":"2020","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.apsb.2022.06.011_bib26","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1038\/s41467-018-05767-4","article-title":"The gut microbiota promotes hepatic fatty acid desaturation and elongation in mice","volume":"9","author":"Kindt","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2022.06.011_bib27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41467-020-14430-w","article-title":"Mtorc2-AKT signaling to ATP-citrate lyase drives brown adipogenesis and de novo lipogenesis","volume":"11","author":"Martinez Calejman","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2022.06.011_bib28","doi-asserted-by":"crossref","first-page":"11805","DOI":"10.1074\/jbc.RA119.008708","article-title":"Enhanced acetylation of ATP-citrate lyase promotes the progression of nonalcoholic fatty liver disease","volume":"294","author":"Guo","year":"2019","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.06.011_bib29","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.molcel.2013.07.002","article-title":"Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growth","volume":"51","author":"Lin","year":"2013","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2022.06.011_bib30","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/ATVBAHA.116.308963","article-title":"Prevention of diet-induced metabolic dysregulation, inflammation, and atherosclerosis in LDLR\u2012\/\u2012 mice by treatment with the ATP-citrate lyase inhibitor bempedoic acid","volume":"37","author":"Samsoondar","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2022.06.011_bib31","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1161\/ATVBAHA.118.311212","article-title":"Metformin and amp kinase activation increase expression of the sterol transporters ABCG5\/8 (ATP-binding cassette transporter g5\/g8) with potential antiatherogenic consequences","volume":"38","author":"Molusky","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2022.06.011_bib32","doi-asserted-by":"crossref","first-page":"9557","DOI":"10.1074\/jbc.M310512200","article-title":"ATP-citrate lyase deficiency in the mouse","volume":"279","author":"Beigneux","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.06.011_bib33","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/hep.22774","article-title":"Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice","volume":"49","author":"Wang","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2022.06.011_bib34","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1194\/jlr.M003335","article-title":"Deficiency in hepatic ATP-citrate lyase affects VLDL-triglyceride mobilization and liver fatty acid composition in mice","volume":"51","author":"Wang","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2022.06.011_bib35","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.molmed.2017.09.001","article-title":"Targeting ATP-citrate lyase in hyperlipidemia and metabolic disorders","volume":"23","author":"Pinkosky","year":"2017","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.apsb.2022.06.011_bib36","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","article-title":"Mendelian randomization study of acly and cardiovascular disease","volume":"380","author":"Ference","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2022.06.011_bib37","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.ejmech.2018.09.001","article-title":"Atp citrate lyase (acly) inhibitors: an anti-cancer strategy at the crossroads of glucose and lipid metabolism","volume":"157","author":"Granchi","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2022.06.011_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2019.101006","article-title":"ATP-citrate lyase (acly) in lipid metabolism and atherosclerosis: an updated review","volume":"77","author":"Feng","year":"2020","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.apsb.2022.06.011_bib39","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2022.06.011_bib40","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the clear wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.apsb.2022.06.011_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2022.06.011_bib42","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1161\/ATVBAHA.117.310676","article-title":"Bempedoic acid lowers low-density lipoprotein cholesterol and attenuates atherosclerosis in low-density lipoprotein receptor-deficient (LDLR+\/\u2012 and LDLR\u2012\/\u2012) yucatan miniature pigs","volume":"38","author":"Burke","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2022.06.011_bib43","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1194\/jlr.M030528","article-title":"AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism","volume":"54","author":"Pinkosky","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2022.06.011_bib44","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1039\/C5CC08096G","article-title":"Rational design and synthesis of substrate-product analogue inhibitors of \u03b1-methylacyl-coenzyme a racemase from mycobacterium tuberculosis","volume":"52","author":"Pal","year":"2016","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.apsb.2022.06.011_bib45","doi-asserted-by":"crossref","first-page":"48275","DOI":"10.1074\/jbc.M310223200","article-title":"ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion","volume":"278","author":"Graf","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2022.06.011_bib46","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/HYPERTENSIONAHA.111.180406","article-title":"Indices of obesity and cardiometabolic risk","volume":"58","author":"Whaley-Connell","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.apsb.2022.06.011_bib47","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0140-6736(10)62038-7","article-title":"National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants","volume":"377","author":"Farzadfar","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2022.06.011_bib48","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMra1806939","article-title":"Lipid management for the prevention of atherosclerotic cardiovascular disease","volume":"381","author":"Michos","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2022.06.011_bib49","series-title":"Clinical pharmacokinetics and pharmacodynamics. Encyclopedia of pharmaceutical science and technology","first-page":"473","author":"Grover","year":"2013"},{"key":"10.1016\/j.apsb.2022.06.011_bib50","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41586-019-1094-6","article-title":"An allosteric mechanism for potent inhibition of human ATP-citrate lyase","volume":"568","author":"Wei","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2022.06.011_bib51","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-59745-019-5_13","article-title":"Isolation and culture of adult mouse hepatocytes","volume":"633","author":"Li","year":"2010","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.apsb.2022.06.011_bib52","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41401-020-0472-9","article-title":"Ampk activator c24 inhibits hepatic lipogenesis and ameliorates dyslipidemia in HFHC diet-induced animal models","volume":"42","author":"Sun","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2022.06.011_bib53","first-page":"4585","article-title":"Rat liver microsome-mediated N-demethylation and mutagenicity of azoxymethane","volume":"38","author":"Campbell","year":"1978","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2022.06.011_bib54","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nm1540","article-title":"Brain glucose metabolism controls the hepatic secretion of triglyceride-rich lipoproteins","volume":"13","author":"Lam","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2022.06.011_bib55","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/ATVBAHA.112.246066","article-title":"Liver x receptor agonist modulation of cholesterol efflux in mice with intestine-specific deletion of microsomal triglyceride transfer protein","volume":"32","author":"Xie","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2022.06.011_bib56","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cmet.2010.12.004","article-title":"Inhibition of srebp by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques","volume":"13","author":"Tang","year":"2011","journal-title":"Cell Metab"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383522002775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383522002775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:59:42Z","timestamp":1761929982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383522002775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2211383522002775"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2022.06.011","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2022.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}